Dyadic International (DYAI) EPS (Basic) Growth (1y) (2019 - 2026)
Powered by 
Analysis
Dyadic International (DYAI) EPS (Basic) Growth (1y) (2019 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.46 Bn | 192.47 Bn | 7.24 Bn | 65.24% |
| 2 | Gilead Sciences | 179.92 Bn | 176.75 Bn | 6.22 Bn | -636.10% |
| 3 | Vertex Pharmaceuticals | 131.37 Bn | 123.51 Bn | 2.84 Bn | 7.74% |
| 4 | Regeneron Pharmaceuticals | 81.86 Bn | 73.87 Bn | 3.93 Bn | -4.72% |
| 5 | Argenx Se | 60.29 Bn | 55.10 Bn | 1.37 Bn | 87.85% |
| 6 | Moderna | 53.76 Bn | 48.62 Bn | 52.00 Mn | 7.59% |
| 7 | Alnylam Pharmaceuticals | 33.16 Bn | 29.85 Bn | 992.69 Mn | 322.67% |
| 8 | Biogen | 31.90 Bn | 30.62 Bn | 1.96 Bn | -84.77% |
| 9 | Roivant Sciences | 29.13 Bn | 29.13 Bn | 1.16 Mn | - |
| 10 | Dyadic International | 18.38 Mn | 10.42 Mn | - | 21.72% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 21.72% |
| Dec 31, 2025 | 9.84% |
| Sep 30, 2025 | -914.74% |
| Jun 30, 2025 | 13.60% |
| Mar 31, 2025 | 6.19% |
| Dec 31, 2024 | 28.15% |
| Sep 30, 2024 | 90.07% |
| Jun 30, 2024 | 10.14% |
| Mar 31, 2024 | -5.61% |
| Dec 31, 2023 | 4.93% |
| Sep 30, 2023 | 12.07% |
| Jun 30, 2023 | 34.92% |
| Mar 31, 2023 | 30.29% |
| Dec 31, 2022 | 50.01% |
| Sep 30, 2022 | 46.12% |
| Jun 30, 2022 | 16.38% |
| Mar 31, 2022 | 99.92% |
| Dec 31, 2021 | -112.14% |
| Sep 30, 2021 | -30.03% |
| Jun 30, 2021 | -44.13% |